martes, 28 de enero de 2020

FDA Continues Strong Support of Innovation in Development of Gene Therapy Products | FDA

FDA Continues Strong Support of Innovation in Development of Gene Therapy Products | FDA



FDA Continues Strong Support of Innovation in Development of Gene Therapy Products

Guidances issued today provide regulatory clarity for product developers


This is a pivotal time in the field of gene therapy as the FDA continues its efforts to support innovators developing new medical products for Americans and others around the world. To date, the FDA has approved four gene therapy products, which insert new genetic material into a patient’s cells. The agency anticipates many more approvals in the coming years, as evidenced by the more than 900 investigational new drug (IND) applications for ongoing clinical studies in this area. The FDA believes this will provide patients and providers with increased therapeutic choices.

In that spirit, today, the FDA is announcing the release of a number of important policies: six final guidances on gene therapy manufacturing and clinical development of products and a draft guidance, Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations.

No hay comentarios: